Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(23)
DRUG(9)
BIOLOGICAL(1)
Rituximab
3 trials
phase_1phase_2
md-anderson-cancer-center
Busulfan
3 trials
phase_1phase_2
md-anderson-cancer-center
Cyclophosphamide
2 trials
phase_1_2phase_2
md-anderson-cancer-center
Melphalan
2 trials
phase_1phase_2
md-anderson-cancer-center
Vorinostat
2 trials
phase_1phase_2
md-anderson-cancer-center
Peripheral Blood Stem Cell Transplantation
2 trials
phase_1phase_2
md-anderson-cancer-center
Autologous Hematopoietic Stem Cell Transplantation
2 trials
phase_2
md-anderson-cancer-center
Gemcitabine
2 trials
phase_1phase_2
md-anderson-cancer-center

+15 more interventions

23 unique interventions3 categories

Analytics

Trial Phases

Phase 12
Phase 24

Trial Status

Completed4
Other1

Role Distribution

Principal Investigator5
PI Rate100%

Activity Timeline

Clinical Trials (5)

NCT04220008Phase 2Withdrawn
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt Lymphoma+4 more
PrincipalinvestigatorStart date: 2021-10-29
NCT04074746Phase 1/2Completed
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Recurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin Lymphoma+7 more
PrincipalinvestigatorStart date: 2020-07-18
NCT03259503Phase 1Completed
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Recurrent Diffuse Large B-Cell LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma+2 more
PrincipalinvestigatorStart date: 2019-09-13
NCT03019640Phase 2Completed
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
Mantle Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+4 more
PrincipalinvestigatorStart date: 2017-10-10
NCT02506959Phase 2Completed
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Plasma Cell LeukemiaPlasmacytomaRecurrent Plasma Cell Myeloma+1 more
PrincipalinvestigatorStart date: 2015-09-14

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Alex F Herrera

City of Hope Medical Center

Related
9 trials

Shared therapeutic areas:

Refractory Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+11 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score15%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Lymphoma, Mantle-CellRecurrent Plasma Cell MyelomaRefractory Hodgkin Lymphoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Shaji Kumar

Mayo Clinic

Related
10 trials

Shared therapeutic areas:

Recurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaLeukemia, Plasma Cell+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Luhua (Michael) Wang

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Lymphoma, Mantle-CellRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)
Similarity Score3%

William Wegener, MD, PhD

Gilead Sciences

Related
12 trials

Shared therapeutic areas:

Lymphoma, Mantle-CellPlasmacytoma
Similarity Score2%

Isidro Jarque, MD

Hospital Universitario La Fe

Related
1 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score1%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score1%

Maria José Ramírez Sánchez, MD

Hospital del SAS Jerez

Related
1 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score1%

Secundino Ferrer, MD

Hospital Dr. Peset

Related
1 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score1%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT04220008Phase 2PrincipalInvestigator

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt Lymphoma+4 more
Withdrawn
NCT04074746Phase 1/2PrincipalInvestigator

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Recurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin Lymphoma+7 more
Completed
NCT03259503Phase 1PrincipalInvestigator

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Recurrent Diffuse Large B-Cell LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma+2 more
Completed
NCT03019640Phase 2PrincipalInvestigator

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Mantle Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+4 more
Completed
NCT02506959Phase 2PrincipalInvestigator

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Plasma Cell LeukemiaPlasmacytomaRecurrent Plasma Cell Myeloma+1 more
Completed

All 5 trials loaded